Compare GRNQ & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRNQ | OSRH |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Malaysia | United States |
| Employees | N/A | 22 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 17.9M |
| IPO Year | 2014 | N/A |
| Metric | GRNQ | OSRH |
|---|---|---|
| Price | $1.78 | $0.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.1K | ★ 1.6M |
| Earning Date | 05-13-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,673,997.00 | N/A |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.55 | N/A |
| 52 Week Low | $1.10 | $0.38 |
| 52 Week High | $3.18 | $1.79 |
| Indicator | GRNQ | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 39.49 |
| Support Level | $1.63 | $0.40 |
| Resistance Level | $1.88 | $0.47 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 76.47 | 15.23 |
Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.